Association of medical treatment nonadherence with all-cause mortality in newly treated hypertensive US veterans

Hypertension

Volumn 64, Issue 5, 2014, Pages 951-957

  Gosmanova, Elvira O ^a   Lu, Jun L ^a   Streja, Elani ^b   Cushman, William C ^a,c   Kalantar Zadeh, Kamyar ^b   Kovesdy, Csaba P ^a,c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Antihypertensive agents; Medication nonadherence; Mortality

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARBONATE DEHYDRATASE INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LOOP DIURETIC AGENT; PERIPHERAL VASODILATING AGENT; POTASSIUM SPARING DIURETIC AGENT; RENIN INHIBITOR; THIAZIDE DIURETIC AGENT;

ADULT; ARTICLE; BLACK PERSON; BLOOD PRESSURE VARIABILITY; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; ICD-9; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT REFUSAL; VETERAN; AGED; CODING; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PROPENSITY SCORE; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CLINICAL CODING; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MORTALITY; PATIENT COMPLIANCE; PROPENSITY SCORE; UNITED STATES; VETERANS;

EID: 84922391679     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.03805     Document Type: Article

References (40)

1. Roger VL, Go AS, Lloyd-Jones DM, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation. 2012;125:e2-e220.
2. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-520.
3. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
4. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA. 2003;289:2534-2544.
5. Yoon PW, Gillespie CD, George MG, Wall HK; Centers for Disease Control and Prevention (CDC). Control of hypertension among adults-National Health and Nutrition Examination Survey, United States, 2005-2008. MMWR Morb Mortal Wkly Rep. 2012;61(Suppl):19-25.
6. Gu Q, Burt VL, Dillon CF, Yoon S. Trends in antihypertensive medication use and blood pressure control among United States adults with hypertension: the National Health And Nutrition Examination Survey, 2001 to 2010. Circulation. 2012;126:2105-2114.
7. Elliott WJ. Improving outcomes in hypertensive patients: focus on adherence and persistence with antihypertensive therapy. J Clin Hypertens (Greenwich). 2009;11:376-382.
8. Burke TA, Sturkenboom MC, Lu SE, Wentworth CE, Lin Y, Rhoads GG. Discontinuation of antihypertensive drugs among newly diagnosed hypertensive patients in UK general practice. J Hypertens. 2006;24:1193-1200.
9. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119:3028-3035.
10. Esposti LD, Saragoni S, Benemei S, Batacchi P, Geppetti P, Di Bari M, Marchionni N, Sturani A, Buda S, Esposti ED. Adherence to antihypertensive medications and health outcomes among newly treated hypertensive patients. Clinicoecon Outcomes Res. 2011;3:47-54.
11. Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V, Borghi C, Brignoli O, Caputi AP, Cricelli C, Mantovani LG. Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009;120:1598-1605.
12. Breekveldt-Postma NS, Penning-van Beest FJ, Siiskonen SJ, Falvey H, Vincze G, Klungel OH, Herings RM. The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Curr Med Res Opin. 2008;24:121-127.
13. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297:177-186.
14. Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158:825-830.
15. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604-612.
16. US Department of Veterans Affairs, VA Information Resource Center (VIReC). VIReC Research User Guide: VHA Pharmacy Prescription Data, 2nd ed. Hines, IL: VIReC. 2008.
17. Molnar MZ, Kalantar-Zadeh K, Lott EH, Lu JL, Malakauskas SM, Ma JZ, Quarles DL, Kovesdy CP. Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease. J Am Coll Cardiol. 2014;63:650-658.
18. Kovesdy CP, Lott EH, Lu JL, Malakauskas SM, Ma JZ, Molnar MZ, Kalantar-Zadeh K. Hyponatremia, hypernatremia, and mortality in patients with chronic kidney disease with and without congestive heart failure. Circulation. 2012;125:677-684.
19. Kovesdy CP, Lott EH, Lu JL, Malakauskas SM, Ma JZ, Molnar MZ, Kalantar-Zadeh K. Outcomes associated with microalbuminuria: effect modification by chronic kidney disease. J Am Coll Cardiol. 2013;61:1626-1633.
20. VIReC Research User Guide. VHA Medical SAS Inpatient Datasets FY 2006-2007. Hines, IL: U.S. Department of Veterans Affairs. VA Information Resource Center; 2007.
21. VIReC. US Department of Veterans Affairs VA Information Resource Center Data Quality Update: Race. Hines, IL: U.S. Department of Veterans Affairs; 2009.
22. Powers BJ, Olsen MK, Smith VA, Woolson RF, Bosworth HB, Oddone EZ. Measuring blood pressure for decision making and quality reporting: where and how many measures? Ann Intern Med. 2011;154:781-788, W-289-790.
23. Nord J, Stults B, Rose R, Underwood AE, Williams T, West G, Huhtala T, Milne CK. Optimizing office blood pressure measurement at a vamc. Fed Pract. 2012;29:35-39.
24. Choudhry NK, Shrank WH, Levin RL, Lee JL, Jan SA, Brookhart MA, Solomon DH. Measuring concurrent adherence to multiple related medications. Am J Manag Care. 2009;15:457-464.
25. Arnold N, Sohn MW, Maynard C, Hynes DM. VIReC Technical Report 2: VA-NDI Mortality Data Merge Project. Hines, IL: US Department of Veterans Affairs, US Department of Veterans Affairs, Veterans Affairs Information Resource Center; 2006.
26. D'Agostino RB Jr. Propensity scores in cardiovascular research. Circulation. 2007;115:2340-2343.
27. Gerber BS, Cho YI, Arozullah AM, Lee SY. Racial differences in medication adherence: a cross-sectional study of Medicare enrollees. Am J Geriatr Pharmacother. 2010;8:136-145.
28. Lewey J, Shrank WH, Bowry AD, Kilabuk E, Brennan TA, Choudhry NK. Gender and racial disparities in adherence to statin therapy: a metaanalysis. Am Heart J. 2013;165:665-78, 678.e661.
29. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens. 2005;23:2101-2107.
30. GALLUP Well-Being. GALLUP Healthways Well-Being Index. New York, NY: GALLUP; 2012.
31. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000;160:2101-2107.
32. Dunbar-Jacob J, Mortimer-Stephens MK. Treatment adherence in chronic disease. J Clin Epidemiol. 2001;54(Suppl 1):S57-S60.
33. World Health Organization. Adherence to Long-Term Therapies: Evidence for Action. Geneva, Switzerland: World Health Organization; 2003.
34. Turner BJ, Hecht FM. Improving on a coin toss to predict patient adherence to medications. Ann Intern Med. 2001;134:1004-1006.
35. Vitolins MZ, Rand CS, Rapp SR, Ribisl PM, Sevick MA. Measuring adherence to behavioral and medical interventions. Control Clin Trials. 2000;21(5 Suppl):188S-194S.
36. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105-116.
37. Mancia G, Fagard R, Narkiewicz K, et al; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-1357.
38. Austin PC. An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011;46:399-424.
39. Hodgson TA, Cai L. Medical care expenditures for hypertension, its complications, and its comorbidities. Med Care. 2001;39:599-615.
40. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43:521-530.